Drug effects on cardiac myosin adenosine triphosphatase activity.
D000251:Adenosine Triphosphatases / Q000378:metabolism*; D000255:Adenosine Triphosphate; D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001665:Binding Sites; D002118:Calcium / Q000494:pharmacology; D002698:Chloralose / Q000494:pharmacology; D003521:Cyclopropanes / Q000494:pharmacology; D004077:Digoxin / Q000494:pharmacology; D004285:Dogs; D004837:Epinephrine / Q000494:pharmacology; D004987:Ethers / Q000494:pharmacology; D006321:Heart / Q000187:drug effects*; D006333:Heart Failure / Q000201:enzymology; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D008012:Lidocaine / Q000494:pharmacology; D008274:Magnesium / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects; D009124:Muscle Proteins; D009206:Myocardium / Q000201:enzymology; D009609:Nitrous Oxide / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D010042:Ouabain / Q000494:pharmacology; D010424:Pentobarbital / Q000494:pharmacology; D010600:Pharmacology; D011342:Procainamide / Q000494:pharmacology; D011485:Protein Binding; D011802:Quinidine / Q000494:pharmacology; D012631:Secobarbital / Q000494:pharmacology
D003521:Cyclopropanes; D004987:Ethers; D009124:Muscle Proteins; D000804:Angiotensin II; D012631:Secobarbital; D002698:Chloralose; D010042:Ouabain; D004077:Digoxin; D000255:Adenosine Triphosphate; D008012:Lidocaine; D000251:Adenosine Triphosphatases; D008274:Magnesium; D010424:Pentobarbital; D011802:Quinidine; D009609:Nitrous Oxide; D011342:Procainamide; D007545:Isoproterenol; D002118:Calcium; D009638:Norepinephrine; D004837:Epinephrine